Description
NSE notifies listing and trading of 1,74,80,782 bonus equity shares of Kilitch Drugs (India) Limited (KILITCH) effective March 27, 2026, with record date of March 24, 2026.
Summary
NSE has notified the listing and trading of equity shares issued pursuant to a bonus issue by Kilitch Drugs (India) Limited (symbol: KILITCH). A total of 1,74,80,782 new equity shares will be admitted to dealings on the NSE Capital Market segment effective March 27, 2026.
Key Points
- 1,74,80,782 bonus equity shares of Kilitch Drugs (India) Limited to be listed on NSE
- Symbol: KILITCH | ISIN: INE729D01010
- Distinctive number range: 17480783 to 34961564
- Circular issued under Regulation 3.1.1 of NSE (Capital Market) Trading Regulations Part A
- Securities will be identified by designated codes for trading purposes
Regulatory Changes
No new regulatory changes. This circular is issued in accordance with Regulation 3.1.1 of the National Stock Exchange (Capital Market) Trading Regulations Part A, which governs admission of securities to dealings on the exchange.
Compliance Requirements
- Members must use the designated security codes (symbol: KILITCH) to identify and trade these securities on the trading system.
- No additional compliance action required for members beyond standard trading procedures.
Important Dates
- Circular Date: March 20, 2026
- Record Date: March 24, 2026
- Deemed Date of Allotment: March 25, 2026
- Effective Date for Listing & Trading: March 27, 2026
Impact Assessment
The bonus issue increases the total share count of Kilitch Drugs (India) Limited, doubling the float (from ~1.75 crore to ~3.5 crore shares based on the distinctive number range). Existing shareholders will receive additional shares proportionally. The listing of bonus shares may exert short-term downward pressure on the share price as the share count increases, but the overall market capitalization remains unchanged at the time of allotment. Impact is limited to existing shareholders and traders of KILITCH stock.
Impact Justification
Routine bonus issue listing notification for a mid-cap pharma company; affects existing shareholders of KILITCH but has no broad market-wide regulatory impact.